Hologic Inc. has announced that 11 studies featuring the Breast Cancer Index $(BCI)$ Test will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). The studies include new data on premenopausal women and comparative analyses of BCI Testing with the 21-gene assay for extended endocrine therapy decision-making in early-stage, hormone receptor-positive breast cancer. These findings are intended to support personalized treatment recommendations and explore the expanded utility of the BCI Test across diverse patient subgroups and sample types. The results from these studies have not yet been presented and are scheduled for future presentation at SABCS 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hologic Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201515278) on December 02, 2025, and is solely responsible for the information contained therein.